Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Turku | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF). There are yet limited real life data on outcomes following elective cardioversion in AF patients treated with NOACs. The aim of this study is to investigate the complications and the use of NOACs in AF patients undergoing cardioversion.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and predictors of thromboembolic complications | 31 days after cardioversion of persistent AF | |
| Incidence and predictors of bleeding | 31 days after cardioversion of persistent AF |
| Measure | Description | Time Frame |
|---|---|---|
| Number of recurrence of AF | 31 days after cardioversion of persistent AF | |
| Hemodynamic complications of cardioversion | 31 days after cardioversion of persistent AF |
Not provided
Inclusion Criteria:
Exclusion Criteria:
-
Not provided
Not provided
Not provided
Not provided
AF patients undergoing cardioversion.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mika Lehto, MD, PhD | Helsinki University Central Hospital | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
| D013568 |
| Pathological Conditions, Signs and Symptoms |